VIVS
VivoSim Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.28
+1.00%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$4.67M
MomentumView details →
1D Return
+1.00%
YTD Return
−84.52%
RSI (14)
31.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$4.67M
RSI (14)
31.6
MomentumView details →
1D Return
+1.00%
YTD Return
−84.52%
SummaryUpdated Jun 1, 2026
VivoSim Labs, Inc. (NASDAQ:VIVS) is a biotechnology company founded in 2007 and headquartered in San Diego, California. The company went public in February 2012 and was formerly known as Organovo Holdings, Inc. before changing its name to VivoSim Labs in April 2025. VivoSim operates at the intersection of biotechnology and advanced manufacturing, developing innovative 3D tissue technologies for drug development and therapeutic applications. The company has evolved from a pure-play bioprinting technology provider to a clinical-stage biotechnology company with both platform technology offerings and proprietary drug candidates in development.
Similar companies
Latest newsMore news →
VivoSim Labs, Inc. received a notice from NASDAQ on August 17, 2026, stating that the company is not in compliance with Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum bid price of $1.00 per share, and the company has until February 16, 2027, to regain compliance.15d agoVivoSim enters the Chinese market with the first commercial sales of its NAMkind™ toxicology screening and efficacy testing services.45d ago